Myasthenia Gravis Overview and Pathophysiology

Written by Margaret Anne Rockwood | Last updated March 13, 2026
Medically reviewed by Nizar Souayah, MD

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by varying degrees of skeletal muscle weakness and abnormal fatigability. Although relatively rare, MG has been studied extensively as a prototypical antibody-mediated autoimmune disease, providing crucial insights into neuromuscular transmission and immunopathogenesis in multiple neuromuscular diseases.

Epidemiology and Clinical Presentation

MG affects individuals across a wide age range and shows a bimodal age distribution: younger adults (more commonly women) and older adults (more often men). The U.S. prevalence is approximately 150-250 per million people.

It is not a directly inherited genetic disease, but there is a genetic susceptibility component.

MG is rare enough that primary care physicians — and some neurologists —may never see a case. Presentation can mimic other diseases such as cranial nerve palsies, multiple sclerosis, ALS, and, less commonly, Parkinson’s disease. Early differential diagnosis is critical, as early interventions can often prevent irreversible damage.

MG patients present with fluctuating muscle weakness that worsens with activity and improves with rest. Common early symptoms include ptosis (drooping eyelids) and diplopia (double vision).

Bulbar weakness is also a common symptom that may lead to difficulty swallowing, speaking, and chewing. As MG progresses (often within 1–3 years), it usually generalizes to larger muscles, causing limb weakness, chewing/swallowing fatigue, slurred speech, shortness of breath or neck weakness. These fluctuate daily —less in the morning, getting worse as the day progresses, and intensifying with activity.

Generalized weakness may involve respiratory muscles. If not treated, myasthenic crisis —a potentially life-threatening respiratory failure— can occur.

Classification

MG is classified clinically by the distribution of weakness (ocular versus generalized) and the serology that indicates the individual’s autoantibody profile. The four main serologic types are:

• AChR-positive MG: The most common form (80-85% of all MG cases); autoantibodies target the nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction.
• MuSK-positive MG: Autoantibodies target muscle-specific kinase (MuSK), leading to distinct clinical features that include prominent bulbar weakness (difficulty swallowing and speaking), neck and respiratory muscle involvement, rapid onset of generalized weakness and, often, poor response to acetylcholinesterase inhibitors. Ocular symptoms are less common than in AChR-positive MG.
• LRP4 and other antigen-associated MG: Less frequent antibody specificities have been identified in LRP4 MG (1-5% of MG cases). Symptoms are often milder, with predominantly ocular or limb weakness, slower progression, and less frequent respiratory involvement compared with AChR- or MuSK-positive MG.
• Seronegative MG: Characterized by no detectable antibodies to known antigens in standard assays, likely reflecting low-titer or unidentified antibody types.

Pathophysiology

As with many autoimmune diseases, downstream effects have been elucidated, while the initial trigger for the disease remains less understood.

What we do know is that MG is a prototype II antibody-mediated disease, characterized by the breakdown of immunologic tolerance to self-antigens such as the AChR, which the body treats as foreign pathogens. The immune system responds by erroneously targeting components of the neuromuscular junction (NMJ). This leads to defective neuromuscular transmission and structural damage to the postsynaptic membrane.

Comparison with Normal Neuromuscular Transmission

In normal neuromuscular transmission:

1. Action potentials travel down the motor neuron to the presynaptic terminal at the neuromuscular junction (NMJ).
2. Acetylcholine (ACh) is released into the synaptic cleft and binds to nicotinic ACh receptors (nAChRs) on the postsynaptic muscle membrane.
3. This binding of ACh and nicotinic ACh (nAChR) receptors opens ligand-gated ion channels, enabling a sodium influx that depolarizes the muscle membrane. This generates an end-plate potential that then triggers the muscle action potential and muscle contraction.
4. Acetylcholinesterase (AChE) in the synaptic cleft then rapidly hydrolyzes ACh, terminating the signal.

This process has a high tolerance for modest deviations in receptor function, with effective muscle activation usually undeterred. However, significant reductions in receptor availability, as seen in MG, lower this tolerance to deviations, exacerbating transmission disruption.

Dysfunction from Anti-AChR Antibodies:

In this most common form of MG, IgG1 and IgG3 subclass antibodies hijack the normal transmission process by targeting and binding with the nicotinic AChR (nAChR) on the postsynaptic muscle membrane.

They contribute to weakness through several mechanisms:

1. Blocked ACh binding: Antibodies bind to receptor sites, physically impeding ACh from binding to these receptors that cluster on the muscle endplate. Functional AChR density may drop to~30% of their normal end-plate potentials. With this drop in density, muscle fibers fail to depolarize reliably.
2. Accelerated internalization and degradation: In AChR-positive MG, antibodies cross-link adjacent AChRs via their bivalent structure, accelerating receptor internalization and degradation.This further depletes postsynaptic receptor density.
3. Complement-mediated damage: The blockages activate a complement cascade, leading to membrane attack complexes (MAC) that injure the postsynaptic membrane, flatten junctional folds, and further reduce effective receptor surface area. These impediments lead to fatigable muscle weakness and a vicious cycle of lowered receptors to receive ACh.

The cumulative effect is reduced functional receptor density, diminished end-plate potential amplitude, and impaired action potential generation in muscle fibers. Once AChR density drops below a critical threshold (~30% of normal), clinical weakness ensues.

Dysfunction Caused by Anti-MuSK Antibodies

Through another mechanism, a smaller subset of patients harbor antibodies against MuSK, a kinase essential for clustering AChRs at the NMJ. MuSK cannot properly interact with LRP4, and the agrin–LRP4–MuSK pathway fails. The antibodies interfere with normal receptor aggregation and NMJ maintenance, producing a variant clinical phenotype.

Patients with anti-MuSK antibodies may be more prone to severe bulbar, facial and respiratory weakness, and frequent myasthenic crises.

Other antibodies

Least commonly, some MG forms are characterized by antibodies against low-density lipoprotein receptor-related protein 4 (LRP4) and agrin. These antibodies disrupt NMJ development and signaling by interfering with the MuSK-LRP4-agrin axis.

Agrin is a large protein secreted from the nerve terminal into the synaptic cleft, where it binds to LRP4 on the muscle membrane. It is important in neuromuscular transmission because it enables activation of MuSK, which, in turn, is needed to signal the AChRs to cluster and anchor at the motor end plate in preparation for depolarization and muscle contraction.

Role of the Thymus

The thymus plays a key role in immune regulation and T-cell maturation. Epithelial and myoid cells within the thymus express AChR, and in MG, a dysfunction may occur that promotes the development of autoreactive T and B cells. This is thought to involve immune cross-reactivity (molecular mimicry) and improper presentation of self-antigens by thymic cells.

Thymic abnormalities like hyperplasia with germinal center formation (benign) are present in ~60-70% of MG cases. A thymoma (slow-growing neoplasm) is present in ~10-15% of MG cases and may be an upstream trigger for the autoimmune responses.

Overview of Treatments

Treatment selection increasingly reflects antibody subtype, disease severity, speed of required response, and patient tolerance, rather than a one-size-fits-all approach.

Options include:

1. Symptomatic drugs like pyridostigmine
2. Broad immunosuppressants such as prednisone and azathioprine.
3. Monoclonal antibody therapies like eculizumab, ravulizumab, efgartigimod, nipocalimab, rituximab and the recently FDA-approved rozanolixizumab-noli that directly interrupt antibody production, persistence, or complement-mediated damage.
4. A new peptide C5 complement inhibitor, zilucoplan, that prevents complement-mediated damage to the neuromuscular junction.
5. Intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) which are also biologic-based immune therapies used for rapid, short-term disease control, including myasthenic crisis.
6. Thymectomy, which improves symptoms or induces remission in selected patients, especially those with thymoma or early generalized MG.

Recap

Myasthenia gravis is a well-characterized autoimmune disorder of the neuromuscular junction. Pathophysiologically, it results from autoantibody-mediated disruption of postsynaptic receptor function and structural integrity, impairing neuromuscular transmission and causing fatigable weakness.

The hallmark symptom of fatigable muscle weakness arises from insufficient neuromuscular transmission during sustained or repetitive activity. With repeated stimulation, ACh stores may be depleted and fewer functional receptors remain available to initiate effective depolarization. This leads to progressive decline in muscle force generation—a pattern reflected clinically as increasing weakness with use. Recovery occurs with rest, but resilience from episodes of weakness falls with progressive depletion of receptors at the NMJ.

Ocular muscles are often affected first, possibly due to their high firing rates and unique NMJ properties. Bulbar and respiratory involvement in advanced disease can lead to life-threatening complications.

Targeted therapies, including monoclonal antibodies and other types of inhibitors of pathogenic mechanisms in MG have resulted in improved clinical outcomes. Compared to traditional therapies, these are associated with lowered relapse rates from nearly two per year to well under one per year. They have facilitated substantial steroid-sparing in many patients and roughly doubled the likelihood of clinically meaningful improvement on standardized outcome scales.

References

1. Myasthenia Gravis: Background, Pathophysiology, Epidemiology. Shah AK. Medscape. Updated Dec 5, 2023.
2. Epidemiology and patient characteristics of the US myasthenia gravis population; real-world evidence from a large insurance claims database. Miller-Wilson LA, et al. (2025). BMJ Neurology Open.
3. Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations. Dresser L, Wlodarski R, Rezania K, Soliven B. J Clin Med. 2021;10(11):2235.
4. Myasthenia gravis: Pathophysiology, diagnosis, and treatment. Tannemaat MR, Huijbers MG, Verschuuren JJGM. Handb Clin Neurol. 2024.
5. Myasthenia gravis: Subgroup classification and therapeutic strategies. Gilhus NE, Verschuuren JJ. Lancet Neurol. 2015;14(10):1023–1036.
6. MuSK antibodies disrupt agrin-induced acetylcholine receptor clustering. Huijbers MG, Zhang W, Klooster R, et al. J Neurosci. 2013;33(5):2071–2082.
7. A comprehensive analysis of the epidemiology and clinical characteristics of LRP4-antibody-positive MG. Zisimopoulou P, Evangelakou P, Tzartos J, et al. J Autoimmun. 2014;52:139–145.
8. Randomized trial of thymectomy in myasthenia gravis. Wolfe GI, Kaminski HJ, Aban IB, et al. N Engl J Med. 2016;375:511–522.
9. Advances in the diagnosis, pathogenesis and treatment of myasthenia gravis. Dalakas MC. Ther Adv Neurol Disord. 2019;12:1–18.
10. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Howard JF Jr, Bril V, Vu T, et al. The Lancet Neurology. 2021;20(7):526–536.
11. Myasthenia Gravis. Suresh, A.B., Asuncion, R.M.D., StatPearls Contributors, NCBI Bookshelf. Updated 2024.
12. The role of complement in the pathogenesis and treatment of myasthenia gravis. Salazar AM, et al. Frontiers in Neurology. 2025.
13. Myasthenia gravis: the future is here. Kaminski, Henry J. Journal of Clinical Investigation. 2024.
14. The muscle is not a passive target in myasthenia. Vilquin JT, et al. Frontiers in Neurology. 2019.